Avidity Biosciences Inc. (RNA) is scheduled to present new long-term efficacy and safety data from its MARINA-OLE trial at the Muscular Dystrophy Association Clinical & Scientific Conference on March 4, 2024.
MARINA-OLE trial is a Phase 2 extension of the MARINA study to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of multiple-doses of lead drug candidate AOC 1001 administered intravenously to adult Myotonic Dystrophy Type 1 (DM1) patients.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.